| Name | Argent Biopharma Limited NPV (DI) |
|---|---|
| Epic | RGT |
| Isin | AU0000326647 |
| Index | MID300 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 6.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £197.19 | Debt ratio | n/a |
| Shares in issue | 3,286.48 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -435.83 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -47.36 | 52-week high / low | 5.79p / 550.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Argent Biopharma Limited NPV (DI) |
|---|---|
| Address | 1202 Hay Stree, West Perth, Australia, WA 6005 |
| Telephone | +61 (8)6382 3390 |
| Website | http://www.mgcpharma.com.au/ |
| Director | Position |
|---|---|
| Mr Nativ Segev | Non-Executive Director |
| Mr Layton Mills | Non-Executive Director |
| Mr Daniel Robinson | Non-Executive Director |
| Mr Brett Mitchell | Non-Executive Chairman |
| Mr Roby Zomer | Managing Director and CEO |
| Assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 30/06/24 | 30/06/23 | 30/06/22 |
| Intangible asssets and goodwill | n/a | n/a | 3.15 |
| Investments and other non-current assets | 1.33 | n/a | n/a |
| Total non-current assets | 8.05 | 7.45 | 12.1 |
| Inventory / work in progress | 0.88 | 1.36 | 1.84 |
| Trade and other receivables | 1.16 | 0.93 | 2.73 |
| Cash and equivalents | 0.7 | 0.24 | 1.89 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 10.79 | 9.98 | 18.56 |
| Liabilities $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 12.18 | 13.33 | 7.71 |
| Long term liabilities | 4.44 | 4.68 | 5.67 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 16.61 | 18.02 | 13.38 |
| Net assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | -5.83 | -8.03 | 5.18 |
| Equity $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 123.29 | 103.69 | n/a |
| Minority interests | -0.67 | -0.63 | -0.66 |
| Retained earnings | -129.67 | -119.17 | n/a |
| Share premium account | n/a | n/a | n/a |
| Total equity | -5.83 | -8.03 | 5.18 |
| Income $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -16.7 | -19.87 | -20.56 |
| Pre-tax profit | -17.55 | -21.13 | -20.77 |